6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
63 citations
,
May 2015 in “PloS one” GALT5 and GALT2 are important for plant growth and development because they help with protein glycosylation.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
February 2026 in “Pediatrics in Review” A newborn with severe low blood sugar due to a genetic issue needed major surgery after standard treatments failed.
2 citations
,
September 2022 in “Cellular and molecular biology” Agaricus bisporus derived β-Glucan could be an effective cervical cancer treatment with antimicrobial and antioxidant properties.
August 2025 in “Bioactive Materials” Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.
2 citations
,
December 2010 in “Zhonghua neifenmi daixie zazhi” AHST shows promise for treating type 1 diabetes but needs more research before widespread use.
8 citations
,
June 1981 in “Clinica Chimica Acta” October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
20 citations
,
January 2013 in “Evidence-based complementary and alternative medicine” TGPC plus CGT is effective and safe for treating severe alopecia areata in children.
April 2019 in “Journal of the Endocrine Society” A woman's severe insulin resistance improved with treatment, but she still had high testosterone levels due to ovarian issues.
4 citations
,
September 2020 in “Frontiers in Microbiology” Algal oligosaccharides help prevent hair loss and promote hair growth.
9 citations
,
January 2014 in “Molecular Genetics and Metabolism Reports” The rhg mutation in mice affects the Oat gene, causing hair growth issues and other symptoms.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
1 citations
,
January 2007 in “The Kitakanto Medical Journal” Effective treatment for UFT overdose includes antibiotics and G-CSF, with bone marrow biopsy and transfusion as backup options.
February 2019 in “Neoreviews” The infant with a urea cycle disorder improved with treatment and a liver transplant.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
27 citations
,
January 2018 in “Drug Delivery” GC10/DOX hydrogel shows promise as an effective thyroid cancer treatment.
January 2023 in “Brazilian Journals Editora eBooks” HPLC may detect prediabetes and diabetes earlier than Immunoturbidimetry because it shows higher A1c levels.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
March 2026 in “ACS Applied Materials & Interfaces” MCP@G improves diabetic wound healing by reducing stress and promoting tissue repair.
6 citations
,
January 1988 in “Japanese Journal of Medicine” Hair glycation levels can indicate long-term blood sugar control.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
18 citations
,
August 2012 in “Chinese journal of integrative medicine/Chinese Journal of Integrative Medicine” Both treatments for alopecia areata are equally effective and safe.